CBFA2T3 is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain CBFA2T3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CBFA2T3 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].